我武生物1月15日获融资买入1490.06万元，融资余额4.30亿元

Core Viewpoint - Iwubio experienced a decline of 0.58% in stock price on January 15, with a trading volume of 173 million yuan, indicating a potential shift in investor sentiment and market dynamics [1] Financing Summary - On January 15, Iwubio had a financing buy amount of 14.90 million yuan and a financing repayment of 36.21 million yuan, resulting in a net financing outflow of 21.31 million yuan [1] - The total financing and securities balance for Iwubio as of January 15 is 430 million yuan, which accounts for 2.66% of its market capitalization, indicating a relatively high financing balance compared to the past year [1] - The company had a securities lending repayment of 1,500 shares on January 15, with no shares sold, and a remaining securities lending balance of 11,300 shares valued at 349,100 yuan, which is low compared to the past year [1] Business Performance - As of September 30, Iwubio reported a total of 32,400 shareholders, a decrease of 6.22% from the previous period, while the average circulating shares per person increased by 6.63% to 14,927 shares [2] - For the period from January to September 2025, Iwubio achieved an operating income of 853 million yuan, representing a year-on-year growth of 16.86%, and a net profit attributable to shareholders of 345 million yuan, reflecting a growth of 26.67% [2] Dividend and Shareholding Information - Since its A-share listing, Iwubio has distributed a total of 965 million yuan in dividends, with 369 million yuan distributed over the past three years [3] - As of September 30, 2025, among the top ten circulating shareholders, Hong Kong Central Clearing Limited is the fourth largest with 5.56 million shares, an increase of 1.45 million shares from the previous period [3] - New institutional shareholders include Jiashi Mutual Fund and Penghua Medical Technology Fund, holding 4.71 million shares and 4.30 million shares respectively, while the China Merchants National Bio-Medical Index Fund reduced its holdings by 783,300 shares [3]